Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adbelizumab plus concurrent chemoradiotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
ChiCTR2400084445Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Henan Cancer Hospital. Primary endpoint: Pathological complete response rate. Planned start May 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400084445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084445.